Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open Label Study of AMDX-2011P as a Retinal Tracer in Participants With Primary Open Angle Glaucoma

NCT06223048 is registered in ClinicalTrials.gov with Amydis Inc. as lead sponsor.

NCT NCT06223048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06223048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open Label Study of AMDX-2011P as a Retinal Tracer in Participants With Primary Open Angle Glaucoma
Lead sponsor
Amydis Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
December 7, 2023
Completion date
February 28, 2025
Enrollment
50 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

primary open angle glaucoma